pp-007 Injection 600 mg - 12 ml
Dossier type
CTD
Dossier status
Ready to file
Country of origin
China
GMP approvals
China
Comments
A humanized IgG4 monoclonal antibody targeting PD-L1, used in combination with chemotherapy for first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). Phase III -Non-small cell lung cancer, Phase II -Cervical cancer; Oesophageal cancer
Manufacturer #17216
Global developer of innovative drugs in oncology, metabolic, autoimmune, and cardiovascular diseases, with 14 in-house products and multiple partnerships. Over 5,000 R&D staff across global centers and strong IP, clinical pipeline, and high-standard manufacturing.
Manufacturer usually replies in 41 days